LTI-03 is under clinical development by Lung Therapeutics and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LTI-03’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LTI-03 overview

LTI-03 is under development for the treatment of idiopathic pulmonary fibrosis. The drug candidate is a caveolin-1 scaffolding domain 7-mer peptide (FTTFTVT). It is administered through inhalational route.

Lung Therapeutics overview

Lung Therapeutics is a pharmaceutical company that offers orphan drug indications for lung injury and diseases. The company provides service to underserved, life-threatening lung condition. Its pipeline candidates include LTI-01, a single chain urokinase plasminogen activator (scuPA), which is used for clearance of fibrinous scar tissue in patients with loculated pleural effusion and LTI-03, a drug product for the treatment of Idiopathic Pulmonary Fibrosis. The company aims to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions. Lung Therapeutics is headquartered in Austin, Texas, the US.

For a complete picture of LTI-03’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.